DK1808164T3 - Vådgranuleringsmetode til fremstilling af farmaceutiske sammensætninger af aripiprazol - Google Patents

Vådgranuleringsmetode til fremstilling af farmaceutiske sammensætninger af aripiprazol

Info

Publication number
DK1808164T3
DK1808164T3 DK06251324T DK06251324T DK1808164T3 DK 1808164 T3 DK1808164 T3 DK 1808164T3 DK 06251324 T DK06251324 T DK 06251324T DK 06251324 T DK06251324 T DK 06251324T DK 1808164 T3 DK1808164 T3 DK 1808164T3
Authority
DK
Denmark
Prior art keywords
aripiprazole
pharmaceutical compositions
wet granulation
granulation method
preparing pharmaceutical
Prior art date
Application number
DK06251324T
Other languages
Danish (da)
English (en)
Inventor
Julia Hrakovsky
Ruth Tenengauzer
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36637023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1808164(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of DK1808164T3 publication Critical patent/DK1808164T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK06251324T 2006-01-05 2006-03-14 Vådgranuleringsmetode til fremstilling af farmaceutiske sammensætninger af aripiprazol DK1808164T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75670806P 2006-01-05 2006-01-05

Publications (1)

Publication Number Publication Date
DK1808164T3 true DK1808164T3 (da) 2009-04-20

Family

ID=36637023

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06251324T DK1808164T3 (da) 2006-01-05 2006-03-14 Vådgranuleringsmetode til fremstilling af farmaceutiske sammensætninger af aripiprazol

Country Status (13)

Country Link
US (1) US8865722B2 (fr)
EP (2) EP2036545A1 (fr)
JP (1) JP4875001B2 (fr)
CN (1) CN101351192A (fr)
AT (1) ATE419837T1 (fr)
CA (1) CA2627693A1 (fr)
DE (1) DE602006004694D1 (fr)
DK (1) DK1808164T3 (fr)
ES (1) ES2318693T5 (fr)
IL (1) IL190916A0 (fr)
PL (1) PL1808164T3 (fr)
PT (1) PT1808164E (fr)
WO (1) WO2007081366A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
TR200604349A2 (tr) 2006-08-15 2008-03-21 NOBEL İLAÇ SANAYii VE TiCARET A.Ş. Aripiprazol içeren farmasötik bileşimler
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
WO2010079506A2 (fr) 2008-06-23 2010-07-15 Torrent Pharmaceuticals Ltd. Composition pharmaceutique d'aripiprazole
CA2773003A1 (fr) 2009-09-15 2011-03-24 Ratiopharm Gmbh Forme pharmaceutique a delitement oral contenant de l'aripiprazole
CN102106826B (zh) * 2009-12-29 2013-06-05 上海中西制药有限公司 一种阿立哌唑固体制剂及其制备方法
KR101897302B1 (ko) * 2010-04-30 2018-09-11 브리스톨-마이어스 스큅 컴퍼니 Ｎ－（４－（２－아미노－３－클로로피리딘－４－일옥시）－３－플루오로페닐）－４－에톡시－１－（４－플루오로페닐）－２－옥소－１，２－디히드로피리딘－３－카르복스아미드를 포함하는 제약 조성물
CN102850268B (zh) * 2011-06-27 2015-07-15 上海中西制药有限公司 阿立哌唑ⅰ型微晶、阿立哌唑固体制剂及制备方法
JO3753B1 (ar) 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
US9717707B2 (en) * 2011-12-08 2017-08-01 Hexal Ag Pharmaceutical statin composition
WO2014104989A1 (fr) * 2011-12-27 2014-07-03 Mahmut Bilgic Compositions pharmaceutiques comprenant de l'aripiprazole
WO2013100878A1 (fr) * 2011-12-27 2013-07-04 Mahmut Bilgic Formulations pharmaceutiques comprenant de l'aripiprazole
WO2013175508A2 (fr) 2012-05-24 2013-11-28 Medreich Limited Composition pharmaceutique stable d'aripiprazole
JP6007169B2 (ja) * 2012-11-30 2016-10-12 大原薬品工業株式会社 アリピプラゾール無水物を含有する固形製剤の製造方法
ES2625613T3 (es) * 2013-04-30 2017-07-20 Otsuka Pharmaceutical Co., Ltd. Preparación sólida oral que comprende aripiprazol y método para producir una preparación sólida oral que comprende aripiprazol
US9051268B2 (en) 2013-04-30 2015-06-09 Otsuka Pharmaceutical Co., Ltd. Oral solid preparation comprising aripiprazole and method for producing oral solid preparation comprising aripiprazole
GR1008442B (el) * 2014-01-16 2015-03-05 "Φαρματεν Α.Β.Ε.Ε.", Φαρμακευτικο σκευασμα περιεχον αριπιπραζολη ή αλας αυτης
EP3002005A1 (fr) * 2014-09-30 2016-04-06 Molkerei Meggle Wasserburg GmbH & Co. Kg Excipient de compression directe à base de lactose, de cellulose et d'amidon
WO2016189504A1 (fr) * 2015-05-28 2016-12-01 Leiutis Pharmaceuticals Pvt Ltd Compositions non lyophilisée d'aripiprazole et procédés de préparation de celles-ci
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA71629C2 (en) * 1999-08-03 2004-12-15 Lilli Icos Llc Composition containing free drug particulate form of ?-carboline (variants), method for its manufacture (variants), and method for treating sexual dysfunction
CA2311734C (fr) 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Forme pharmaceutique orale a dissolution ultra-rapide
US20020076437A1 (en) * 2000-04-12 2002-06-20 Sanjeev Kothari Flashmelt oral dosage formulation
MY129350A (en) 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
TWI324074B (en) 2001-10-09 2010-05-01 Bristol Myers Squibb Co Flashmelt oral dosage formulation
JP2003238393A (ja) 2002-02-15 2003-08-27 Otsuka Pharmaceut Co Ltd 施錠性が改善された錠剤及びその製造方法
DE10224170A1 (de) * 2002-05-31 2003-12-11 Desitin Arzneimittel Gmbh Pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreisetzung
EP1606262A1 (fr) 2003-03-21 2005-12-21 Hetero Drugs Limited Nouvelles formes cristallines d'aripiprazole
WO2004106322A2 (fr) 2003-04-25 2004-12-09 Cadila Healthcare Limited Polymorphes d'aripiprazole
CN101005829A (zh) 2003-10-21 2007-07-25 艾克塔维斯集团公司 喹硫平制剂
JP4836797B2 (ja) 2003-10-23 2011-12-14 大塚製薬株式会社 放出制御性無菌注射アリピプラゾール製剤および方法
ATE529409T1 (de) * 2003-12-16 2011-11-15 Teva Pharma Verfahren zur herstellung von kristallinen aripiprazolformen
ES2684325T5 (es) 2004-01-20 2024-06-10 Novartis Ag Formulación y proceso de compresión directa
US7507823B2 (en) 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
CN101087760B (zh) 2004-11-18 2011-09-28 斯索恩有限公司 结晶的阿立哌唑溶剂化物
CN102627603A (zh) 2004-11-18 2012-08-08 斯索恩有限公司 制备结晶阿立哌唑的方法
EP1686117A1 (fr) 2005-01-27 2006-08-02 Sandoz AG Polymorph et solvates d'aripiprazole
CA2600542A1 (fr) 2005-03-17 2006-09-21 Synthon B.V. Comprimes pharmaceutiques de forme cristalline d'aripiprazole ii
CA2605128A1 (fr) 2005-04-15 2007-01-11 Medichem, S.A. Syntheses et preparations de polymorphes d'aripiprazole cristallin
JP2008540644A (ja) 2005-07-15 2008-11-20 テバ ファーマシューティカル インダストリーズ リミティド 新規粒質化方法及びそれから生成される粒質物
US20070014853A1 (en) 2005-07-15 2007-01-18 Ilan Zalit Pharmaceutical dosage form containing novel pharmaceutical granulate
US20070014864A1 (en) 2005-07-15 2007-01-18 Teva Pharmaceutical Industries, Ltd. Novel pharmaceutical granulate
US20070014854A1 (en) 2005-07-15 2007-01-18 Ilan Zalit Novel granulation process
JP2009508859A (ja) 2005-09-15 2009-03-05 エラン ファーマ インターナショナル リミテッド ナノ粒子アリピプラゾール製剤
WO2007073389A1 (fr) 2005-12-22 2007-06-28 Teva Pharmaceutical Industries Ltd. Formes de dosage solides comprimées comprenant des médicaments de faible solubilité et procédé servant à les fabriquer
US20070148245A1 (en) 2005-12-22 2007-06-28 Ilan Zalit Compressed solid dosage forms with drugs of low solubility and process for making the same
US20070272777A1 (en) 2005-12-22 2007-11-29 Guy Samburski Processes for reducing particle size of aripiprazole
EP1988899A4 (fr) 2006-02-03 2009-12-30 Reddys Lab Ltd Dr Co-cristaux d'aripiprazole
EP1880714A1 (fr) 2006-07-20 2008-01-23 Helm AG Aripiprazole amorphe et son procédé de préparation

Also Published As

Publication number Publication date
ATE419837T1 (de) 2009-01-15
IL190916A0 (en) 2008-11-03
CN101351192A (zh) 2009-01-21
PL1808164T3 (pl) 2009-06-30
DE602006004694D1 (de) 2009-02-26
US8865722B2 (en) 2014-10-21
ES2318693T3 (es) 2009-05-01
ES2318693T5 (es) 2018-10-04
EP1808164A1 (fr) 2007-07-18
PT1808164E (pt) 2009-03-17
EP2036545A1 (fr) 2009-03-18
JP4875001B2 (ja) 2012-02-15
CA2627693A1 (fr) 2007-07-19
WO2007081366A1 (fr) 2007-07-19
EP1808164B2 (fr) 2018-07-04
EP1808164B1 (fr) 2009-01-07
US20070154544A1 (en) 2007-07-05
JP2008531737A (ja) 2008-08-14

Similar Documents

Publication Publication Date Title
DK1808164T3 (da) Vådgranuleringsmetode til fremstilling af farmaceutiske sammensætninger af aripiprazol
NL1030863A1 (nl) Heteroaromatische chinolineverbindingen.
DK1808165T3 (da) Törre formuleringer af aripiprazol
BRPI0810646A2 (pt) " compostos farmacêuticos ".
NL2000690A1 (nl) Gestabiliseerde farmaceutische samenstellingen omvattende fesoterodine.
CL2007001040A1 (es) Proceso para la preparacion de antagonista de la sustancia p derivado de acil-amino-alquilen-amida.
DK2041139T3 (da) Farmaceutiske forbindelser
NL2000480A1 (nl) Nieuwe farmaceutische middelen.
DK2431359T3 (da) Fremgangsmåde til fremstilling af diaminophenothiaziniumforbindelser
DK3984528T3 (da) Farmaceutiske sammensætninger, som omfatter nilotinib
BRPI0812354A2 (pt) Composição farmacêutica não-aquosa.
DK2049487T3 (da) Fremgangsmåde til fremstilling af 2-substituerede 5-(1-alkylthio)alkylpyridiner
CR10353A (es) Nuevos compuestos.
ITMI20071002A1 (it) Manufatto per edilizia.
BRPI0720234A2 (pt) Composição farmacêutica
DK2093217T3 (da) Fremgangsmåde til fremstilling af form X af aripiprazol
DK2213654T3 (da) Fremgangsmåde til fremstilling af 2-amino-5-brombenzamid derivater
BRPI0812234A2 (pt) Composto de quinolona e composição farmacêutica.
FR2923834B1 (fr) Nouvelles compositions polysicocyanates hydrodispersibles.
DK1912961T3 (da) Fremgangsmåde til fremstilling af bepromolin
BRPI0807853A2 (pt) Prendedor para vestuário.
DK1994138T3 (da) Fremgangsmåde til fremstilling af humant g-csf
FR2925058B1 (fr) Maltitol parallelepipede rectangulaire.
BRPI0811431A2 (pt) Composição farmacêutica aquosa.
FR2903669B3 (fr) 02isse demontable.